Business

Figures converted from KRW at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Know the Business

Mirae is a sub-scale Korean test-handler vendor whose FY2025 financials are the by-product of one Chinese customer's capex decision. The economic engine is custom-built capital equipment paid for in stage deposits; the moat is thin; the cycle is violent; and the headline P/E disguises a business that ran negative operating cash flow last year because the same revenue surge that produced reported profit also blew up working capital. After the FY2025-low-to-now rally the market is now pricing the equity at ~1.0× book — the question is not whether that is cheap, but whether the equity is durable.

1. How This Business Actually Works

Mirae sells two products, but one matters: ATE test handlers were 89% of FY2025 revenue and SMT chip mounters / linear motors were 11%. Each handler is a six-figure custom-built machine that loads packaged chips, thermally conditions them, presents them to a separately-purchased "tester" and sorts the survivors. The plant in Cheonan ran at 97.5% utilization in FY2025, producing 90 ATE units and 13 SMT units — the entire business is, physically, about a hundred handlers a year.

Per-unit figures are segment revenue (new equipment plus spares and service) divided by units shipped — they overstate the change in a pure ASP because year-over-year spares/service mix moves with the installed base. The directional read still holds: FY2025 added volume at a markedly lower per-unit revenue.

FY2025 ATE units jumped from 23 → 90 (4×) but segment revenue per unit fell from $0.67M to $0.35M. This is what a single mega-order from one customer looks like — Mirae traded ASP for volume to land YILINING PRECISION. The capacity is small enough that one buyer can absorb most of it; the pricing power is small enough that one buyer can dictate the deal.

The 30/60/10 cash structure is why Mirae's FY2025 net income ($7.0M) bears no resemblance to its operating cash flow (negative $3.6M). When orders triple in a year, deposits cover only part of the build, inventory and receivables swell, and the cash impact lags revenue by six months or more. Mirae is a working-capital-heavy industrial: incremental profit shows up on the income statement long before it shows up in the bank.

Where margin actually comes from. Two levers: utilization and customer mix. The fixed-cost base is roughly $8M/year of operating expenses (SG&A + R&D), barely changed across the FY2021–FY2025 swings. Gross margin moved from 34.7% (FY2021) to -33.9% (FY2023 trough) to 41.8% (FY2025). FY2024's reported 83% gross margin is an accounting anomaly — likely tooling deposits and recovery items recognised as revenue without matched COGS, per the segment disclosure where ATE alone reported $7.8M operating income on $15.3M revenue. The clean read: at ~$35M revenue and 90+ handlers a year, this business earns 18-20% operating margins. Below ~$20M revenue, it loses money.

2. The Playing Field

Mirae sits at the long-tail bottom of the test-handler universe — two to three orders of magnitude smaller than the global benchmarks, and roughly a third the revenue of Techwing. The peer set splits into three economic tiers: a global leader (Advantest), a Korean back-end ecosystem champion (Hanmi Semi), and a cluster of sub-scale cyclicals (Cohu, Techwing, ISC, Mirae) where margins live or die on the cycle.

Latest FY for each peer; FX at period-end. Mirae market cap and multiples computed at the 2026-05-21 close of ₩27,600 (4.47M shares ≈ ₩123.4B / ~US$82M); P/B uses FY2025-end equity of US$84.6M; P/E uses FY2025 net income of US$7.0M; EV/EBITDA uses FY2025 EBITDA of US$7.0M and FY2025-end net cash of US$3.0M. Cohu and Techwing margins reflect the down-leg of the back-end cycle; Mirae, Hanmi, and Advantest the up-leg.

Scale and product mix decide margins. Advantest and Hanmi sit at the top — both make products with real switching costs. Cohu is loss-making at $453M revenue because handlers alone do not generate enough recurring service revenue to absorb fixed engineering cost in a normal year. Techwing runs sub-scale at $110M and a 10% margin. Mirae posted 18% only because FY2025 was an exceptional volume year courtesy of one customer.

What "good" looks like in this industry is product adjacency to HBM or being the tester, not handler scale. Hanmi Semi proves the point: $398M revenue, 44% op margins, $21.2B market cap. Mirae's standard test handlers are not on that road, and the valuation reflects it: ~1.0× P/B at current price versus Hanmi at 30×+.

3. Is This Business Cyclical?

Mirae is deeply cyclical — beyond what "cyclical" means for a typical industrial. Four years swung revenue $44M → $17M → $18M → $35M (-61%, +24%, +88%) and operating margin from +15% → -84% → +39% → +18%. There is no normalized year in this dataset because the company never spent two years in the same state.

Three places the cycle hits, in order of investor relevance:

The cycle pattern matters because it puts the FY2024 print (83% gross margin, 39% operating margin) in context: an accounting catch-up year sandwiched between a wipeout (FY2023) and a volume surge (FY2025). The next downturn — when Chinese memory capex slows or YILINING reduces orders — would look like FY2023 again: gross profit goes negative, operating losses approach $10-14M, and equity is consumed at roughly $20M/year of run-rate burn until new capital arrives.

4. The Metrics That Actually Matter

Standard ratios (P/E ~12 at current price, ROE 8.9%, current ratio 3.04) flatter this business. Below are the five readings that actually tell you whether the next twelve months are heading up or down.

The metric that does the most work is the OCF/NI gap. A handler vendor in a true up-cycle should convert ~70–80% of net income to operating cash over a two-year window. Mirae converted roughly −29% over FY2024-FY2025 combined ($7.0M + $4.5M = $11.5M NI; -$3.6M + $0.2M = -$3.4M OCF). The reported earnings did not produce cash, and the missing cash had to be raised through equity (financing CF +$6.5M in FY2025) and $4.5M of new long-term debt — the first long-term debt this company has carried in the data window.

5. What Is This Business Worth?

The right lens is through-cycle EV/revenue floored by book value, not a current P/E. The two segments (ATE 89%, SMT 11%) are economically similar; there is no listed subsidiary or hidden stake to unpick. The single segmentation question is "what is normalized revenue?" — and the answer depends almost entirely on whether the one Chinese customer stays.

The honest framing. Two reasonable values bracket the equity:

• Floor: 0.4–0.6× book = $34–51M. What the market pays when it does not believe through-cycle earnings cover the cost of capital — this is where Mirae traded at year-end 2025 ($42.6M / 0.50× book).
• Up-cycle fair value: 8–10× normalized EBITDA of $3.5M = $28–35M EV → $31–38M equity after net cash. The current market cap of $81.5M sits well above this band, paying a premium for the FY2025 P&L to extend.

At the current $18.22 spot, the market has moved through book value and is now pricing in cycle continuation. The investment case turns on whether the YILINING revenue stream is durable enough to lift normalized EBITDA above $3.5M sustainably. If it is, $70M+ equity is defensible. If not, $35–50M is the right number. No projection of segment economics or DCF will tighten that range; only customer evidence will.

6. What I'd Tell a Young Analyst

Read this company as a levered bet on one Chinese customer's capex plus a Korean handler vendor's equity floor. Everything else is noise.

Watch four things. First, every quarterly DART disclosure for the major-customer note — when YILINING's share moves below 40%, the business has diversified; above 55%, the concentration is structural. Second, the single-supply contract notices (단일판매공급계약) — the only forward-looking signal Mirae publishes. Third, operating cash flow versus net income — if the gap widens in FY2026, the up-cycle was a working-capital illusion and the next downturn will be financed by equity. Fourth, share count drift — a flat share count for two consecutive years would itself be a thesis-changing event.

What the market may be missing: the FY2025 surge looks like a top-line breakthrough but came at a 50% per-unit revenue cut and burned cash. What it may be over-rewarding: at ~1.0× book the margin of safety that was real at year-end 2025 (P/B 0.50) has compressed, and FY2023-style downturns can vaporise $20-28M of equity in eighteen months. The thesis-killer is not weak guidance — it is one Korean exchange filing showing the top customer changed.

Do not over-think this name. It is a small, levered, customer-concentrated cyclical with a 100-handler-a-year ceiling, owned by a controlling shareholder that changed in 2023, with a 16:1 reverse split last year as evidence of past balance-sheet stress. Value it at book, demand a discount for capital-structure history, and own it only if you have an independent reason to believe the China customer relationship is good for two more years.